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Diagnostic capability was determined by calculating the area 
under the curve (AUC) in the receiver operating 
characteristic (ROC) curves. This parameter had an AUC value 
of 0.786. It was predictive of G2-G3 complications with 71.4% 
specificity and 72.2% sensibility for a dose difference 
threshold of 48 Gy. 
 
Conclusion: A non-homogenous dose region around urethra at 
the end of the real-time implant is a risk factor for 
development of urethral morbidity.  
Several studies have found dosimetry correlations between 
CT post-plan and urinary morbidity. This study focuses on US 
real-time dosimetry parameters. It allows us to consider new 
constraints and dosimetry alerts during treatment planning.  
A prospective study is under consideration, where a new 
constraint of a 40-50 Gy maximum dose difference around a 
2.5-mm expansion of the urethra will be implemented if 
feasible. 
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Purpose or Objective: The PSA level after definitive 
treatment using radiotherapy decreases but still remains 
detectable. The aim of this study is to analyze clinical and 
dosimetric factors which influence the PSA level in the blood 
serum of patients with prostate cancer after HDR (High Dose 
Rate) brachytherapy. 
 
Material and Methods: 53 patients after HDR brachytherapy 
were qualified to the study from June 2008 to December 
2010. The patients were from T1c to T2c , iPSA from 1.5 to 
19.6 ng / ml with prostate adenocarcinoma (Gleason Scale < 
7) and belonged to the low and intermediate risk of 
recurrence. 20 patients had androgen deprivation therapy. 
Patients were treated with HDR brachytherapy 3 x 15 Gy or 3 
x 10.5 Gy. Median follow-up was 3 years. The PSA Bounce 
threshold was >0.2 ng/ml and the biochemical failure 
definition was nadir PSA +2.0 ng/ml. The influences of 
clinical and dosimetric parameters were assessed . Statistical 
analysis was performed assuming significance level p < 0.05. 
 
Results: PSA Bounce occurred in 22% after average 10.7 
months. The time to PSA increase in BF group after 
brachytherapy HDR was 36 months. It was observed that 
patients with PSA nadir below 0.1 ng/ml were more likely to 
have normal follow-up than PSA Bounce, biochemical failure 
(BF), clinical failure (CF). The amplitude of the PSA increases 
were significantly different between subgroups. The further 
analysis demonstrated only a significant difference between 
the subgroup HDR_Bounce (median 0.7 ng/ml) and HDR_BF 
(median 2.6 ng/ml). The time to PSA increase was 
significantly different between the subgroups of the group 
HDR. It applies to patients with PSA Bounce (median 10.5 
months) and biochemical failure (median 36 months). The 
analysis of others dosimetric and clinical factors (including 
hormonotherapy) didn’t show any significant effect on the 
studied HDR subgroups. 
 
Conclusion: The percentage of patients who had a PSA 
Bounce was 22%. Predisposing factors for PSA Bounce after 
HDR brachytherapy were nadir PSA (median> 0.1 ng / ml) and 
time to PSA increase (median <12 months). There was no 
influence of other analyzed clinical, dosimetric factors and 
use of hormone therapy to occurrence of the PSA Bounce. 
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Purpose or Objective: To evaluate evolution and average 
time to IPSS (International Prostate Symptom Score) 
recovery, in patients who have been submitted to I-125 
prostate brachytherapy (Low dose rate brachytherapy). 
 
Material and Methods: Between March 2011 and December 
2013 we performed 66 prostate brachytherapy in patients 
with low / intermediate risk prostate cancer. 4 patients also 
received external radiotherapy. 14 patients received previous 
hormone therapy. A 145 Gy dose was prescribed if exclusive 
brachytherapy was given and 108 Gy if combined with 
external radiotherapy. All patients were treated with 
Quicklink Delivery System® (BARD) and real-time 
planification. Of the 66 treated patients 5 did not have initial 
IPSS, 13 did not have complete follow up, and the 48 
remaining have a suitable follow up. The variables that have 
been evaluated were: Prostate volume, Qmax, number of 
implanted seeds, number of needles and Urethra´s D1; “p 
value” was obtained from Mann-Whitney test. The prostate 
average volume was 33.73 cc, Qmax: 18.7 ml/sec, number of 
seeds: 60.2, number of needles: 16.1 and urethra`s D1: 138% 
to the prescribed dose. 
 
Results: With an average follow up of 27 months, 41 of 48 
patients (85.4%) recovered their IPSS, with an average 
recovery time of 9 months. 7 patients (15%) showed 
progressive worsening without recovery, and 3 (4.5%) of them 
developed acute urinary retention (AUR) one month after the 
implant. In a multivariate analysis the main factor that 
influenced AUR was the prostate volume, with p= 0.0583, (in 
these 3 patients prostate volume average was 42.47 cc, 
higher than the average non AUR) and other factors that 
seem to influence were IPSS and Qmax values, without 
statistical significance ("p" value) (In these patients Qmax 
average was 7.63 and IPSS average was 9.33, worse than non 
AUR). 
 
Conclusion: 85% of patients with complete follow-up, 
recovered its basal IPSS. The average time to recovery was 9 
months, and the incidence of acute urinary retention was 
lower than 4.5%.  
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Purpose or Objective: To evaluate biochemical progression-
free survival (BDFS) in men 60 years of age or younger with 
prostate cancer who underwent exclusive permanent 
brachytherapy 
 
Material and Methods: 528 patients(p) with LR/IR. T1:423p 
T2: 105p; Gleason 6: 520p, gleason 7: 8p; neoadyuvant 
hormonotherapy: 48p.; initial PSA≤10: 492p, > 10: 36p. Md 
follow-up 63m (1-173m). BDFS was defined ASTRO definition. 
Patients were selected from RECAP database, helped by 
URONCOR and GEG groups. 
 
Results: Dosimetry: pD90: md147 Gy (45-215 gy); pD90 > 165 
Gy: 19.8%; pD100: md86.2 Gy; pV150: md54.6% prostate 
volumen: 36 cc (14-93 cc) . D10 urethra: md142%(112-191 %); 
D2cc rectum: 79.2 %.Toxicity: Acute: genitourinary: g2: 6.1%; 
g3: 0.6%; rectal: g2: 20%, g3: 3.7%. Late: genitourinary: g2: 
7.7%; g3: 4.6%; rectal: g2: 2%, g3: 0.5%. Both were related 
with pV150: Acute GUg≥2: 71.7% (pV150> 50%) vs. 28.1% 
(<50%); late GUg≥2: 81.8% (> 50%) vs. 18.2% (<50%). p:ns. For 
the entire group, 40p had biochemical failure; 25p localF, 7p 
regionalF and 5p metastases and 5 p (1.05%) dead with 
prostate cancer. The actuarial 5-year and 10-y BDFS was 
93.2% and 88.7%. Overall survival at 5y: 97.3% and 10y: 
91.7%. No factor had influence in the analysis of prognostic 
factors of BDFS. However BDFS 10y pD90 < 145 Gy: 86% vs. 
D90 145-165Gy: 87.8% vs. D90 > 165 Gy: 92.5% (HR: 1.47, p: 
0.46). 
 
Conclusion: This is one of the biggest series at the moment 
in younger men with permanent brachytherapy. Patients 60 
years of age or younger have a high probability of 10-year 
BDFS. There is a trend to get better results with D90> 165 Gy. 
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Purpose or Objective: To investigate the interobserver 
variability in contouring of rectum in high-dose rate 
brachytherapy (HDRBT) for the treatment of prostate 
carcinoma. The HDV dosimetric parameters are obtained and 
reported in accordance with the GEC/ESTRO 
recommendations. 
 
Material and Methods: Four blinded observers 
retrospectively contoured the rectum of five patients treated 
with HDRBT in the radiation oncology department. A 
contouring consensus was previously established to agree in 
the anatomical limits determination in the rectal contouring. 
HDV dosimetric parameters analyzed were the included on 
the GEC-ESTRO recommendations: D0.1cc, D1cc and D2cc and 
the rectal volume were calculated. These endpoints were 
compared between and within the observers. The coefficient 
of variation (CV) defined as a measure of the spread of data 
as a proportion of its mean (expressed as a percentage), was 
estimated to assess the interobserver variation. For each 
parameter, the mean and SD of the two measurements 
recorded (taken with one week apart) from the treatment 
planning study made by transrectal ultra-sonogram (TRUS) 
were estimated for each of the 4 observers. The effect of 
interobserver variation in the total dose recorded was 
analyzed by estimating the accumulative dose (EQD2) for the 
rectum. For our study, the dosimetric parameter to rectum 
was evaluated regarding to single 15Gy prostate HDRBT plan 
and assuming that rectum received full-dose EBRT (46 Gy). 
The total EQD2 (equivalent dose in  
2 Gy per fraction, assuming alpha/beta ratio of 3) doses were 
estimated. 
 
Results: The patient data are represented in Table 1 showing 
the results of the mean reported D0.1cc, D1cc and D2cc for 
the rectum contoured twice for each case. The interobserver 
coefficient of variation for reported D0.1cc, D1cc and D2cc 
was 5.7%(SD 6,28), 4.5%(SD 1,94) and 4%(SD 2,24), 
respectively. The total D2cc parameter for the patients with 
the highest interobserver variation in rectum delineation, 
may result in recorded rectum dose difference up to 2,6 Gy 
by EQD2. 
 
 
 
Conclusion: Interobserver variations in reported parameters 
were high for the D0.1cc (CV: 16%) in a worst-case scenario. 
Even if the D2cc parameter corresponds to low interobserver 
variation, we found that the greatest variation is present in 
high prostate volume cases. Variation in delineation of the 
rectum may be a potential source of uncertainty in the BT 
planning and delivery process. Nevertheless, in our study the 
impact of interobserver variation on the total dose (EQD2) for 
the reported D2cc has a mean of +/- 1.5 Gy. This study 
represents a small analysis of a single center experience, but 
it will be completed with a multicenter study in a second 
part. 
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Purpose or Objective: High Dose Rate Brachytherapy (HDR-
BT) as stand-alone treatment is gaining popularity as salvage 
strategy for patients (pts) with an isolated, intraprostatic 
Prostate Cancer (PCa) recurrence after External Beam 
Radiotherapy (EBRT) and may represent the only treatment 
available for the management of pts diagnosed with PCa and 
challenging clinical scenarios (for ex, pts previously 
irradiated in the pelvis for other primaries). We present a 
retrospective analysis of our series of PCa pts managed with 
HDR-BT alone with particular emphasis on dosimetry and 
early toxicity results. 
 
Material and Methods: From March 2014 to June 2015, 13 pts 
have been treated with HDR-BT alone in our centre: nine 
with salvage intent for an intraprostatic relapse after EBRT, 
and four for primary management after pelvic EBRT for other 
malignancies (follicular lymphoma, rectal cancer and B-cell 
